OpenPV Signal Explorer
FAERS disproportionality dashboard
Reaction

Vulvovaginal Candidiasis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 1,317 reports · 44 co-occurring drugs

As of the last recalculation, Vulvovaginal Candidiasis appears in 1,317 FAERS reports alongside 44 co-occurring drug terms. The strongest observed disproportionality signal is DRS. CLOTRIMAZOLE (PRR 49.1).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
DrugCo-reportsPRRROR
Drs. Clotrimazole3549.149.3
Family Wellness Clotrimazole3549.149.3
Clotrimazole Topical3549.149.3
Clotrimazole3546.246.4
Etonogestrel And Ethinyl Estradiol4633.934.0
Trimethoprim2230.030.0
Bimekizumab2720.420.5
Fluconazole7818.618.7
Itraconazole1317.817.8
Ado-Trastuzumab Emtansine917.017.0
Dapagliflozin3216.516.5
Miconazole Nitrate916.416.4
Canagliflozin3016.216.2
Nystatin Ointment2616.016.0
Nystatin Cream2615.916.0
Adalimumab-Fkjp4515.915.9
Adalimumab-Aaty4515.515.5
Nystatin2615.315.3
Haloperidol2214.514.6
Haloperidol Lactate2214.314.3
Adalimumab-Adaz4614.214.3
Secukinumab12913.913.9
Fexofenadine1413.513.5
Midazolam2113.413.4
Alpelisib712.812.8
Midazolam Hydrochloride2112.512.5
Pertuzumab2011.811.8
Diclofenac Potassium, Film Coated611.311.3
Diclofenac Potassium Tablets611.311.3
Copper2710.110.1
Filgrastim229.49.4
Empagliflozin378.98.9
Diclofenac Potassium68.88.8
Pyrazinamide58.48.4
Ocrelizumab328.38.3
Docetaxel Anhydrous307.27.2
Docetaxel307.27.2
Ofatumumab125.85.8
Drospirenone And Ethinyl Estradiol145.05.1
Conjugated Estrogens And Medroxyprogesterone Acetate74.74.7
Levonorgestrel524.24.2
Dornase Alfa54.04.0
Ixekizumab83.43.4
Etonogestrel62.02.0

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.